

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2025-26/09

May 26, 2025

**To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051**

**To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort, Mumbai -
400 001**

Symbol: AKUMS**Scrip Code: 544222****Sub: Outcome of Board Meeting held on 26th May, 2025**

Respected Sir/Madam,


In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 26th May, 2025 has inter-alia considered and approved the following:

1. The Un-audited (Standalone & Consolidated) Financial Results for the quarter ended 31st March, 2025, and Audited (Standalone & Consolidated) Financial Results for the year ended 31st March, 2025, along with the Audit Reports thereon, as received from the Statutory Auditors, Walker Chandiook & Co. LLP, Chartered Accountants. Copies of such financial results along with the Audit Reports thereon are enclosed herewith as **Annexure-A**.

Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is enclosed herewith as **Annexure-A1**.

Statement of Deviation for the quarter ended 31st March, 2025 is enclosed herewith as **Annexure- B**.

2. Re-appointment of M/s. Balwinder & Associates, Cost Auditor of the Company for F.Y. 2025-26 at remuneration of Rs. 1,60,000/- subject to the ratification of shareholders at the ensuing Annual General Meeting of the Company.



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as **Annexure-C**.

- Appointment of M/s. SPG & Associates, Companies Secretaries as a Secretarial Auditor of the Company for five financial years starting from F.Y. 2025-26 to F.Y. 2029-30 subject to the approval of shareholders at the ensuing Annual General Meeting of the Company.

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as **Annexure-D**.

- Accepted resignation of Mr. Amrut Medhekar, CEO (CDMO) of the Company w.e.f 15.07.2025.

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as **Annexure-E**. A copy of his resignation letter stating reason is enclosed herewith.

- Notice of 21st Annual General Meeting (AGM) of the Company which is scheduled to be held on Friday, 18th July, 2025 at 11:00 AM IST through Video Conferencing/Other Audio-Visual Means. The notice convening the AGM along with the Integrated Annual Report for the financial year ended 31st March, 2025, will be sent in due course.


The Board Meeting commenced at 02:00 PM and concluded at 4:42 PM.

This is for your kind information and record.

Thanking You

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Company Secretary & Compliance Officer
Encl: as above



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India
T +91 11 45002219
F +91 11 42787071

Independent Auditor's Report on Standalone Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the audit report of the other auditor on separate financial statements on Akums Employee Benefit Trust ("the Trust") as referred to in paragraph 12 below, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2025.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditor, in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India



Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Emphasis of Matter – Search and Seizure

4. We draw attention to note 7 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. Further, the Company has not received any order/notice/communication on the findings of such investigation by the Income tax department till date. Accordingly, the impact of this matter for the year ended 31 March 2025 and the adjustments (if any) required, is presently not ascertainable.

Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Statement

5. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
6. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
7. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

8. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
9. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Chartered Accountants



Walker ChandioK & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the business activities and financial information of the Company which includes financial information of its Trust, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of the Company of which we are the independent auditors. For the Trust included in the Statement, which have been audited by the other auditor, such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

12. We did not audit the financial statements the Trust included in the Statement whose financial statements reflects total assets of ₹ 3,004.35 million as at 31 March 2025, and the total revenues of ₹ 0.00 million, total net loss after tax of ₹ 0.01 million, and total comprehensive loss of ₹ 0.01 million, and cash inflows (net) of ₹ 0.00 million for the year ended on that date. The Statement also include the Company's share in the net profit (including other comprehensive income) of ₹ 85.89 million for the year ended 31 March 2025 in respect of a LLP, whose financial statements have not been audited



Walker ChandioK & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

by us. These financial statements of the Trust and LLP have been audited by other auditor, whose reports have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Trust and LLP, is based solely on the reports of such other auditor.

Further, the aforementioned financial statements of this Trust has been prepared in conformity with the Accounting Standards specified under section 133 of the Act, read with the Companies (Accounting Standards) Rules, 2021. The Company's management has converted these financial statements of this Trust to the accounting principles enunciated under the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as applicable to the Company. We have audited these conversion adjustments made by the Company's management.

Our opinion is not modified in respect of the above matters with respect to our reliance on the work done by and the reports of the other auditor.

13. The Statement includes the financial results for the quarter ended 31 March 2025, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.
14. The Statement includes figures for the corresponding quarter ended 31 March 2024 which are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2024 and the unaudited year-to-date figures up to the third quarter of the previous financial year, which have been approved by the Company's Board of Directors, but have not been subjected to audit or review.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Tarun

Tarun Gupta

Partner

Membership No. 507892

UDIN: ~~255078928MNSLV4730~~

Place: New Delhi

Date: 26 May 2025



Statement of audited standalone financial results for the quarter and year ended 31 March 2025

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Year ended	
		31 March 2025	31 December 2024	31 March 2024	31 March 2025	31 March 2024
		(refer note 3)	Unaudited	(refer note 8 and 9)	Audited	Audited
I	Income					
	Revenue from operations	3,287.53	3,374.07	2,983.54	13,117.84	14,441.19
	Other income	320.50	338.42	266.64	1,241.92	941.21
	Total income (I)	3,608.03	3,712.49	3,250.18	14,359.76	15,382.40
II	Expenses					
	Cost of materials consumed	2,070.63	2,066.24	1,705.31	8,110.58	8,672.35
	Changes in inventories of finished goods and work-in-progress	3.49	78.54	131.00	(100.50)	64.42
	Employee benefits expense	538.36	503.40	468.03	2,017.36	1,752.80
	Finance costs	26.26	22.94	47.95	153.09	183.13
	Depreciation and amortisation expense	100.93	106.83	90.86	395.45	326.94
	Fair value changes to financial instruments (refer note 5)	-	-	852.30	(38.67)	3,577.74
	Other expenses	497.81	385.65	432.23	1,744.08	1,640.46
	Total expenses (II)	3,237.48	3,163.58	3,727.68	12,281.39	16,217.84
III	Profit/ (loss) before exceptional items and tax (I-II)	370.55	548.91	(477.50)	2,078.37	(835.44)
IV	Exceptional items	-	-	(12.89)	-	(193.89)
V	Profit/ (loss) before tax (III-IV)	370.55	548.91	(490.39)	2,078.37	(1,029.33)
VI	Tax expense					
	Current tax					
	for current period	82.61	131.17	47.00	492.74	469.90
	for earlier years	-	(0.60)	-	3.90	13.50
	Deferred tax (credit)/ charge					
	for current period	12.05	6.66	41.29	(7.14)	141.78
	for earlier years	-	-	-	(21.11)	-
	Total tax expense	94.66	137.23	88.29	468.39	625.18
VII	Profit/ (loss) for the period/ year (V-VI)	275.89	411.68	(578.68)	1,609.98	(1,654.51)
VIII	Other comprehensive income					
	Items that will not be reclassified to statement of profit and loss					
	Re-measurement gains/(losses) on defined benefit plans	(0.77)	2.57	2.67	(0.96)	(29.07)
	Tax effect relating to these items	0.19	(0.64)	(0.67)	0.24	7.32
IX	Total comprehensive income for the period/ year (VII+VIII) (comprising profit/ (loss) for the period/ year and other comprehensive income, net of tax)	275.31	413.61	(576.68)	1,609.26	(1,676.26)
X	Paid-up share capital (net off shares held by ESOP trust) (refer note 11)	306.21	306.21	286.13	306.21	286.13
XI	Other equity				22,746.26	1,152.65
XII	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*					
	Basic and diluted	1.80	2.69	(4.04)	10.76	(11.56)

*EPS for the quarters have not been annualised

(Handwritten signatures)



Akums Drugs and Pharmaceuticals Limited

CIN: L24239DL2004PLC125888

Audited standalone statement of assets and liabilities as at 31 March 2025

(₹ in million, unless otherwise stated)

Particulars	As at	As at
	31 March 2025	31 March 2024
	Audited	Audited
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	2,647.05	2,507.76
(b) Right-of-use assets	702.12	446.24
(c) Capital work-in-progress	537.11	85.66
(d) Investment property	184.88	188.63
(e) Intangible assets	26.02	30.82
(f) Intangible assets under development	30.24	0.86
(g) Financial assets		
(i) Investments	3,660.14	1,389.24
(ii) Loans	10,443.39	10,716.68
(iii) Others financial assets	100.44	93.67
(h) Non-current tax assets (net)	58.59	46.87
(i) Other non-current assets	127.31	115.41
Total non-current assets	18,517.29	15,621.84
(2) Current assets		
(a) Inventories	2,016.89	1,617.03
(b) Financial assets		
(i) Trade receivables	2,061.37	2,337.94
(ii) Cash and cash equivalents	764.92	689.57
(iii) Bank balances other than (ii) above	2,796.25	43.53
(iv) Others financial assets	204.87	246.31
(c) Other current assets	487.51	397.00
Total current assets	8,331.81	5,331.38
(3) Assets held for sale	-	1.03
Total assets	26,849.10	20,954.25
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	286.13
(b) Other equity	22,746.26	1,152.65
Total equity	23,052.47	1,438.78
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	156.25
(ii) Lease liability	401.77	387.15
(iii) Other financial liabilities (refer note 5)	97.84	13,738.05
(b) Provisions	129.31	113.52
(c) Deferred tax liabilities (net)	74.63	103.13
Total non-current liabilities	703.55	14,498.10
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	39.30	2,106.61
(ii) Lease liability	21.80	20.60
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	225.20	121.99
Total outstanding dues of creditors other than micro and small enterprises	1,970.35	1,527.15
(iv) Other financial liabilities	684.12	1,031.13
(b) Other current liabilities	94.78	155.90
(c) Provisions	57.11	53.99
(d) Current tax liabilities (net)	0.42	-
Total current liabilities	3,093.08	5,017.37
Total equity and liabilities	26,849.10	20,954.25



(₹ in million, unless otherwise stated)

Particulars	Year ended	
	31 March 2025	31 March 2024
	Audited	Audited
A. Cash flow from operating activities		
Net profit/ (loss) before tax	2,078.37	(1,029.33)
Adjustments for:		
Depreciation and amortisation	395.45	326.94
Bad debts	-	7.74
Diminution in the value of investment in subsidiaries	-	1.43
Loans given written off	-	192.46
Fair value changes on financial instruments	(38.67)	3,577.74
Provision for expected credit loss on trade receivable	74.01	27.96
Provision on advance to suppliers	20.00	-
Loss on sale of property, plant and equipment	0.56	2.89
Interest expense	153.09	183.13
Interest income	(973.11)	(749.22)
Gain on reassessment of right-of-use assets	(34.79)	-
Liability no longer required written back	(37.36)	(1.71)
Share of profit from investment in Limited Liability Partnership (LLP)	(85.89)	(89.35)
Rental income	(39.94)	(39.95)
Employee discount on issue of shares	15.60	-
Income tax refund receivable	(19.25)	-
Operating profit before working capital changes	1,508.07	2,410.73
Adjustments for movement in working capital changes:		
(Increase)/ decrease in inventories	(399.86)	354.17
Decrease in trade receivables	202.56	187.69
Decrease/ (increase) in other financial assets	35.75	(93.66)
Increase in other assets	(87.82)	(20.43)
Increase/ (decrease) in trade payables	583.77	(130.58)
(Decrease)/ increase in other financial liabilities	(400.59)	54.92
Increase in provisions	17.95	0.61
(Decrease)/ increase in other liabilities	(61.12)	78.51
Cash flow generated from operations	1,398.71	2,841.96
Less: taxes paid (net)	(488.69)	(362.89)
Net cash flow generated from operating activities (A)	910.02	2,479.07
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including investment property, capital work-in-progress, capital advances and payable towards property, plant and equipment)	(956.18)	(718.59)
Proceeds from sale of property plant and equipment	20.23	7.94
Advance against assets held for sale	-	1.03
Investment in subsidiaries	(2,270.90)	(0.10)
Investment in/ proceeds from redemption of deposits having original maturity of more than 3 months (net)	(2,750.87)	3.32
Loan given to subsidiary companies / LLP	(16,556.01)	(27,274.35)
Loan repaid by subsidiary companies / LLP	16,829.30	25,514.15
Withdrawals from partnership firm	82.96	23.00
Interest received	973.11	749.22
Rent received	39.94	39.95
Net cash flow (used in) investing activities (B)	(4,588.43)	(1,654.43)
C. Cash flow from financing activities		
Proceeds from issue of shares (net of share issue expenses)	6,373.70	-
Repayment of non-current borrowings	(218.75)	(31.25)
(Repayment)/ proceeds of current borrowings (net)	(2,004.81)	24.41
Payment of principal components of lease liabilities	(243.29)	(17.43)
Payment of interest components of lease liabilities	(31.01)	(37.56)
Interest paid	(122.08)	(145.57)
Net cash flow generated/ (used in) from financing activities (C)	3,753.76	(207.40)
Net increase in cash and cash equivalents (A+B+C)	75.35	617.24
Cash and cash equivalents at the beginning of the year	689.57	72.33
Cash and cash equivalents at the end of the year	764.92	689.57

Notes :-

The above standalone statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.



Notes:

- 1 The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 26 May 2025. These standalone financial results for the quarter and year ended 31 March 2025 have been audited by statutory auditor.
- 2 These standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 35 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- 3 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and unaudited published figures upto the nine months period ended 31 December 2024 which were subject to the limited review by statutory auditors of the Company.
- 4 The Company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares and as a result the equity shares of the Company got listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million. The Company has estimated ₹ 1,116.58 million as IPO related expenses and allocated such expenses between the Company (₹ 426.30 million has been adjusted to the securities premium account) and selling shareholders (₹ 690.28 million) in proportion to the equity shares allotted to the public as fresh issue by the Company and under the offer for sale by selling shareholders respectively. Out of the total IPO proceeds the funds available in public offer account is ₹ 513.13 million for remitting funds for pending IPO related expenses. The Company has received an amount of ₹ 6,373.70 million (net of IPO expenses of ₹ 426.30 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

Objects	Planned net proceeds as per prospectus	Actual net proceeds	Utilisation upto 31 March 2025	Unutilised amount as on 31 March 2025
Repayment/prepayment of all or certain borrowings of the Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of the subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of the Company	550.00	550.00	550.00	-
Pursuing inorganic growth initiatives through acquisitions	278.70	278.70	197.30	81.40
General corporate purposes	1,675.00	1,675.00	1,675.00	-
Total proceeds	6,373.70	6,373.70	6,292.30	81.40

The net IPO proceeds of ₹ 81.40 million which were unutilised as at 31 March 2025 has been temporarily invested in fixed deposit by the Company.

- 5 The Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Company to buyback its equity shares at fair market value in case the Company and/ or its promoters were not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the standalone financial results of the Company which has been shown separately in the aforementioned standalone financial results. However, on 29 May 2024, the Investor has waived off these rights in entirety and the Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these standalone financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from other financial liabilities to other equity thereby increasing the net worth.
- 6 The Company operates in only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segment is not applicable and accordingly not made.
- 7 During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company. During the search and seizure proceedings, the Company fully cooperated and provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Company continued without any disruptions, except some minor operational hiccups, while customer commitments were met during this period. The Company has not received any written order/ notice/ communication as the findings of such investigation from the department except for receipt of summons basis which the management is in the process of submitting the requested details to the authorities. There have been no demands which have been raised on the Company as of date. Based on the foregoing and having regard to the matters of the inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these standalone financial results for the quarter and year ended 31 March 2025 in this regard.
- 8 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2024 and management certified year to date figures upto the nine months period ended 31 December 2023.
- 9 The standalone financial results for the quarter ended 31 March 2024 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this quarter provide a true and fair view of the Company's affairs.
- 10 During the quarter ended 31 March 2025, as part of Company's overseas expansion strategy, the Company incorporated a subsidiary in UK, Akums Healthcare UK Limited, with an initial investment of GBP 1 done for incorporation purposes.
- 11 The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Company.

For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited


Sanjeev Jain
Managing Director


Sandeep Jain
Managing Director

DIN: 00323433

DIN: 00323476

Place: New Delhi
Date: 26 May 2025



Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India
T +91 11 45002219
F +91 11 42787071

Independent Auditor's Report on Consolidated Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the year ended 31 March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial statements/ financial information of the subsidiaries as referred to in paragraph 13 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group, for the year ended 31 March 2025.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 13 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Emphasis of Matter – Search and seizure

4. We draw attention to note 8 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025, at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. Further, the Group has not received any order/notice/communication on the findings of such investigation by the Income tax department till date. Accordingly, the impact of this matter for the year ended 31 March 2025 and the adjustments (if any) required, is presently not ascertainable.

Our opinion is not modified in respect of this matter.

Responsibilities of Management and Those Charged with Governance for the Statement

5. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit or loss and other comprehensive income, and other financial information of the Group in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
6. In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
7. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

8. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
9. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

Chartered Accountants



Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the financial information/ financial statements of the entities within the Group, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
10. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
12. We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

13. We did not audit the annual financial statements of 7 subsidiaries included in the Statement whose financial information reflects total assets of ₹ 5,230.33 million as at 31 March 2025, total revenues of ₹ 2,123.31 million, total net loss after tax of ₹ 715.78 million, total comprehensive loss of ₹ 719.50 million, and net cash inflows of ₹ 29.65 million for the year ended on that date, as considered in the Statement. These annual financial statements have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the audit reports of such other auditors, and the procedures performed by us as stated in paragraph 12 above.

Our opinion is not modified in respect of this matters with respect to our reliance on the work done by and the reports of the other auditors.

The Statement includes the annual financial information of 1 subsidiary which have not been audited, whose annual financial information reflect total assets of ₹ nil as at 31 March 2025, total revenues of ₹ nil, total net profit after tax of ₹ nil, total comprehensive income of ₹ nil for the year ended 31 March 2025, and net cash inflows of ₹ nil for the year then ended. This financial information has been furnished to us by the Holding Company's management. Our opinion, in so far as it relates to the amounts and disclosures included in respect of aforesaid subsidiary, is based



Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

solely on such unaudited financial information. In our opinion, and according to the information and explanations given to us by the management, this financial information is not material to the Group.

Our opinion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.

14. The Statement includes the consolidated financial results for the quarter ended 31 March 2025, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.
15. The Statement includes consolidated figures for the corresponding quarter ended 31 March 2024 which are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2024 and the published unaudited year-to-date figures up to the third quarter of the previous financial year, which have been approved by the Holding Company's Board of Directors, but have not been subjected to audit or review.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Tarun

Tarun Gupta

Partner

Membership No. 507892

UDIN: *25507892BMNLSLW8376*

Place: New Delhi

Date: 26 May 2025



Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Akums Drugs and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Annexure 1

List of entities included in the Statement

1. Pure and Cure Healthcare Private Limited
2. Malik Lifesciences Private Limited
3. Maxcure Nutravedics Limited
4. Unosource Pharma Limited
5. Akumentis Healthcare Limited
6. Sarvagunaushdhi Private Limited
7. Plenteous Pharmaceuticals Limited
8. Upadhrish Researchem LLP
9. Nicholas Healthcare Limited
10. Akums Healthcare Limited
11. Qualymed Pharma Private Limited
12. Amazing Research Laboratories Limited*
13. May and Baker Pharmaceuticals Limited*
14. Hygosap Pharma Private Limited (formerly known as Burroughs Welcome Pharmacia Private Limited)*
15. Akums Healthcare UK Limited (w.e.f. 18 March 2025)

Step Down Subsidiary

1. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited)

*Hived off w.e.f. 01 April 2024



Akums Drugs and Pharmaceuticals Limited
 Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034
 CIN: L24239DL2004PLC125888

Email Id: cs@akums.net; Website: www.akums.in

Statement of audited consolidated financial results for the quarter and year ended 31 March 2025

(₹ in million, unless otherwise stated)

S.No.	Particulars	Quarter ended			Year ended	
		31 March 2025	31 December 2024	31 March 2024	31 March 2025	31 March 2024
		(refer note 3)	Unaudited	(refer note 11 and 12)	Audited	Audited
I	Income					
	Revenue from operations	10,555.47	10,104.11	9,442.09	41,181.58	41,781.82
	Other income	175.45	145.61	102.41	521.22	340.25
	Total income (I)	10,730.92	10,249.72	9,544.50	41,702.80	42,122.07
II	Expenses					
	Cost of materials consumed	6,238.45	5,645.98	5,132.99	22,536.08	22,783.70
	Purchase of stock-in-trade	194.90	302.72	634.88	1,814.73	2,595.27
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(42.49)	75.23	(74.72)	(16.47)	123.40
	Employee benefits expense	1,838.97	1,755.98	1,639.54	7,158.21	6,468.64
	Finance costs	45.42	51.34	123.77	346.00	506.14
	Depreciation and amortisation expense	399.97	445.20	339.53	1,534.46	1,256.40
	Fair value changes to financial instruments (refer note 6)	-	-	852.30	(38.67)	3,577.74
	Other expenses	1,386.51	1,110.55	1,227.21	5,082.90	5,003.22
	Total expenses (II)	10,061.73	9,387.00	9,875.50	38,417.24	42,314.51
III	Profit/ (loss) before exceptional items and tax (I-II)	669.19	862.72	(331.00)	3,285.56	(192.44)
	Exceptional items (refer note 7)	(82.17)	(47.81)	(2.17)	(166.97)	260.34
IV	Profit/ (loss) before tax for the period/ year	751.36	910.53	(328.83)	3,452.53	(452.78)
V	Tax expense					
	Current tax					
	for current period	186.81	205.77	81.18	813.67	740.25
	for earlier years	(4.88)	(18.32)	(0.32)	(16.18)	15.18
	Deferred tax charge/ (credit)					
	for current period	(948.80)	49.46	(15.01)	(794.29)	166.67
	for earlier years	22.17	10.50	-	11.56	-
	Adjustment on account of merger :-					
	Income-tax for earlier years	-	-	-	-	(182.90)
	Deferred tax (credit)	-	-	-	-	(1,199.88)
	Total tax expense	(744.70)	247.41	65.85	14.76	(460.68)
VI	Profit/Loss for the period/ year (IV-V)	1,496.06	663.12	(394.68)	3,437.77	7.90
VII	Other comprehensive income					
	- Items that will not be reclassified to profit and loss	(12.55)	2.48	5.42	(13.62)	(50.50)
	- income-tax on items that will not be reclassified to profit and loss	2.39	(0.79)	(1.63)	2.67	13.72
	Other comprehensive income, net of tax	(10.16)	1.69	3.79	(10.95)	(36.78)
VIII	Total comprehensive income for the period/ year (VI+VII) (comprising profit/ (loss) for the period/ year and other comprehensive income, net of tax)	1,485.90	664.81	(390.89)	3,426.82	(28.88)
IX	Profit/ (loss) for the period/ year attributable to:					
	Owners of the Parent	1,476.17	651.82	(413.20)	3,381.76	(40.35)
	Non controlling interest	19.89	11.30	18.52	56.01	48.25
X	Other comprehensive income for the period/ year attributable to:					
	Owners of the Parent	(10.21)	1.82	3.76	(11.03)	(36.56)
	Non controlling interest	0.05	(0.13)	0.03	0.08	(0.22)
XI	Total comprehensive income for the period/ year attributable to:					
	Owners of the Parent	1,465.96	653.64	(409.44)	3,370.73	(76.91)
	Non controlling interest	19.94	11.17	18.55	56.09	48.03
XII	Paid-up share capital (net off shares held by ESOP trust) (refer note 5)	306.21	306.21	286.13	306.21	286.13
XIII	Other equity				30,163.93	6,808.85
XIV	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*	9.64	4.26	(2.89)	22.60	(0.28)
	Basic and diluted					

*EPS for the quarters have not been annualised

(Handwritten signature)



AUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

The Group has reassessed its previously reported segments and decided to report its business segment as a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (API); c) Domestic Branded Formulations; d) International Branded Formulations and e) Trade Generics. Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith :

(₹ in million, unless otherwise stated)

Particulars	Quarter ended			Year ended	
	31 March 2025	31 December 2024	31 March 2024	31 March 2025	31 March 2024
	(refer note 3)	Unaudited	(refer note 11 and 12)	Audited	Audited
I. Revenue from operations (including inter-segment)					
a) CDMO	9,007.57	8,430.41	7,990.69	34,402.42	36,196.31
b) API	666.12	477.88	740.04	2,771.23	2,784.29
c) Domestic Branded Formulations	1,036.52	1,102.00	938.60	4,335.88	3,984.66
d) International Branded Formulations	396.95	424.89	213.36	1,426.13	1,248.11
e) Trade Generics	231.49	324.32	335.03	1,178.79	1,766.50
	11,338.65	10,759.50	10,217.72	44,114.45	45,979.87
II. Revenue from operations (external customers)					
a) CDMO	8,397.60	7,874.42	7,315.87	32,078.76	32,663.47
b) API	501.44	400.56	640.15	2,192.96	2,125.17
c) Domestic Branded Formulations	1,036.52	1,102.00	938.60	4,335.88	3,981.28
d) International Branded Formulations	396.95	424.89	213.36	1,426.13	1,248.11
e) Trade Generics	222.96	302.24	334.11	1,147.85	1,763.79
Revenue from operations	10,555.47	10,104.11	9,442.09	41,181.58	41,781.82

Particulars	Quarter ended			Year ended	
	31 March 2025	31 December 2024	31 March 2024	31 March 2025	31 March 2024
	(refer note 3)	Unaudited	(refer note 11 and 12)	Audited	Audited
III. Segment results before depreciation*					
a) CDMO	886.61	1,213.64	810.21	4,538.92	4,866.92
b) API	(64.62)	(108.94)	(79.84)	(438.01)	(455.14)
c) Domestic Branded Formulations	223.49	203.57	251.38	767.25	684.16
d) International Branded Formulations	87.54	77.90	19.10	275.91	239.02
e) Trade Generics	(99.11)	(83.61)	(72.28)	(282.17)	(332.60)
IV. Segment results**					
a) CDMO	561.38	879.70	535.98	3,323.83	3,886.13
b) API	(139.43)	(210.48)	(149.76)	(757.10)	(736.53)
c) Domestic Branded Formulations	217.61	191.31	250.22	745.74	667.43
d) International Branded Formulations	83.41	73.56	14.19	257.88	218.89
e) Trade Generics	(104.06)	(91.84)	(78.20)	(306.33)	(360.43)
Sub total	618.91	842.25	572.43	3,264.02	3,675.49
Unallocated corporate income/ (expenses) [net]	21.35	2.10	(1,372.79)	66.32	(3,552.23)
Interest income	59.30	54.62	576.50	237.78	120.00
Finance costs	(30.37)	(36.25)	(107.14)	(282.56)	(435.70)
Profit/ (loss) before exceptional items and tax	669.19	862.72	(331.00)	3,285.56	(192.44)
Exceptional items	(82.17)	(47.81)	(2.17)	(166.97)	260.34
Profit/ (loss) before tax	751.36	910.53	(328.83)	3,452.53	(452.78)
Tax expenses	(744.70)	247.41	65.85	14.76	(460.68)
Profit for the period/ year	1,496.06	663.12	(394.68)	3,437.77	7.90
V. Segment assets					
a) CDMO	27,016.32	27,918.56	24,318.00	27,016.32	24,318.00
b) API	4,575.97	4,372.27	4,680.03	4,575.97	4,680.03
c) Domestic Branded Formulations	734.81	803.86	659.73	734.81	659.73
d) International Branded Formulations	813.35	742.49	615.69	813.35	615.69
e) Trade Generics	739.40	923.39	1,550.53	739.40	1,550.53
Less :- Inter-segment eliminations	(735.72)	(845.50)	(783.74)	(735.72)	(783.74)
Segment assets	33,144.13	33,915.07	31,040.24	33,144.13	31,040.24
Un-allocated corporate assets	7,990.29	4,697.64	4,123.41	7,990.29	4,123.41
Total assets	41,134.42	38,612.71	35,163.65	41,134.42	35,163.65
VI. Segment liabilities					
a) CDMO	7,280.97	6,824.73	7,399.40	7,280.97	7,399.40
b) API	601.48	351.87	423.63	601.48	423.63
c) Domestic Branded Formulations	1,100.83	1,263.93	1,105.87	1,100.83	1,105.87
d) International Branded Formulations	512.21	482.36	353.02	512.21	353.02
e) Trade Generics	432.80	501.86	755.40	432.80	755.40
Less :- Inter-segment eliminations	(735.72)	(845.50)	(783.74)	(735.72)	(783.74)
Segment liabilities	9,192.57	8,579.25	9,253.58	9,192.57	9,253.58
Un-allocated corporate liabilities	1,305.74	898.86	18,705.21	1,305.74	18,705.21
Total liabilities	10,498.31	9,478.11	27,958.79	10,498.31	27,958.79

* Segment results before depreciation is calculated as the sum of profit/ (loss) before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense.

** Segment results is calculated as segment results before depreciation less finance costs pertaining to segments and depreciation and amortisation expense.

[Handwritten signatures]



Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	12,286.86	10,649.06
(b) Right-of-use assets	1,614.91	1,171.92
(c) Capital work-in-progress	1,596.17	1,951.33
(d) Goodwill	20.63	20.63
(e) Other intangible assets	51.31	66.04
(f) Intangible assets under development	31.72	2.81
(g) Financial assets		
(i) Investments	1.43	1.43
(ii) Other financial assets	335.56	314.09
(h) Non-current tax assets (net)	123.08	100.21
(i) Deferred tax assets	2,080.65	1,230.63
(j) Other non-current assets	246.01	246.66
Total non-current assets	18,388.33	15,754.81
(2) Current assets		
(a) Inventories	6,809.31	6,304.25
(b) Financial assets		
(i) Trade receivables	7,702.96	8,338.12
(ii) Cash and cash equivalents	1,011.91	1,110.50
(iii) Bank balances other than (ii) above	4,752.60	1,660.03
(iv) Other financial assets	481.28	233.13
(c) Other current assets	1,988.03	1,761.78
Total current assets	22,746.09	19,407.81
(3) Assets held for sale		
	-	1.03
Total assets	41,134.42	35,163.65
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	286.13
(b) Other equity	30,163.93	6,808.85
Equity attributable to equity holders of the Parent	30,470.14	7,094.98
(c) Non-controlling interest	165.97	109.88
Total equity	30,636.11	7,204.86
LIABILITIES		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	782.97
(ii) Lease liabilities	673.27	679.05
(iii) Other financial liabilities	342.44	13,959.46
(b) Provisions	358.97	310.25
(c) Deferred tax liabilities	186.16	121.54
Total non-current liabilities	1,560.84	15,853.27
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	136.55	4,132.58
(ii) Lease liabilities	72.30	57.65
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	772.03	472.25
Total outstanding dues of creditors other than micro and small enterprises	5,655.82	4,849.07
(iv) Other financial liabilities	1,333.27	1,581.37
(b) Other current liabilities	391.41	432.27
(c) Provisions	572.08	565.98
(d) Current tax liabilities (net)	4.01	14.35
Total current liabilities	8,937.47	12,105.52
Total equity and liabilities	41,134.42	35,163.65

James
Low



Statement of audited consolidated cash flow statement for the year ended 31 March 2025

(₹ in million, unless otherwise stated)

Particulars	Year ended	
	31 March 2025	31 March 2024
	Audited	Audited
A. Cash flow from operating activities		
Net profit/ (loss) before tax	3,452.53	(452.78)
Add/ less: non-cash adjustments		
Depreciation and amortisation	1,534.46	1,256.40
Bad debts	2.34	18.74
Provision for expected credit loss on trade receivable	291.77	115.27
Liabilities no longer required, written back	(79.54)	(55.53)
Loss on sale of property, plant & equipment and intangible assets (net)	1.12	3.17
Impairment of assets held for sale	-	8.61
(Reversal of provision earlier recorded)/ losses incurred due to floods	(88.62)	251.73
Finance costs	346.00	506.14
Gain on reassessment of right-of-use assets	(38.27)	(1.38)
Fair value changes on financial instrument	(38.67)	3,577.74
Employee discount on issue of shares	15.60	-
Income tax refund receivable	(19.25)	-
Interest income	(249.86)	(119.99)
Operating profit before working capital changes	5,129.61	5,108.12
Adjustments for working capital changes		
(Increase)/ decrease in inventories	(505.71)	837.29
Decrease / (increase) in trade receivables	341.05	(32.32)
Increase in other assets	(493.00)	(333.70)
Increase/ (decrease) in trade payables	1,192.30	(291.96)
Increase in other financial liabilities	626.08	147.59
Increase in provisions	41.20	104.09
(Decrease)/ increase in other liabilities	(867.23)	67.68
Cash flow generated from operations (gross)	5,464.31	5,606.79
Less: direct taxes paid (net)	(812.35)	(624.20)
Net cash flow generated from operating activities (A)	4,651.96	4,982.59
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital advances and payable towards property, plant and equipment)	(2,723.12)	(3,114.08)
Proceeds from sale of property, plant and equipment	85.47	249.93
Investment in deposits having original maturity of more than 3 months, (net)	(3,090.64)	(634.75)
Advance received against assets held for sale	-	1.03
Loans repaid	-	73.73
Interest received	249.86	119.99
Net cash flow (used in) investing activities (B)	(5,478.43)	(3,304.15)
C. Cash flow from financing activities		
Proceeds from issue of shares (net of offer expenses)	6,373.70	-
Proceeds from non-current borrowings	-	102.94
Repayments of non-current borrowings	(1,238.60)	(358.55)
Proceeds from / (repayment of) current borrowings (net)	(3,540.40)	(236.30)
Payment of principal component of lease liabilities	(521.74)	(84.17)
Payment of interest component of lease liabilities	(62.44)	(69.76)
Interest paid	(282.64)	(434.37)
Net cash flow generated from/(used in) financing activities (C)	727.88	(1,080.21)
Net (decrease)/ increase in cash and cash equivalents (A+B+C)	(98.59)	598.23
Cash and cash equivalents as at the beginning of the year	1,110.50	516.08
Cash and cash equivalents transferred to assets held for sale	-	(3.81)
Cash and cash equivalents as at the end of the year	1,011.91	1,110.50

Note: The above audited consolidated statement of cash flows has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.



Notes :

- The above consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on 26 May 2025. These consolidated financial results for the quarter and year ended 31 March 2025 have been audited by statutory auditor.
- The above consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding company' or 'Parent'), together with its subsidiaries (collectively the 'Group') have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and unaudited published figures upto the nine months period ended 31 December 2024 which were subject to the limited review by statutory auditors of Holding Company.
- The Holding company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share). A discount of ₹ 64 per share was offered to eligible employees bidding in the employee reservation portion of 243,826 equity shares and as a result the equity shares of the Holding company got listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million.
The Holding company has estimated ₹ 1,116.58 million as IPO related expenses and allocated such expenses between the Holding company (₹ 426.30 million has been adjusted to the securities premium account) and selling shareholders (₹ 690.28 million) in proportion to the equity shares allotted to the public as fresh issue by the Holding company and under the offer for sale by selling shareholders respectively. Out of the total IPO proceeds the funds available in public offer account is ₹ 513.14 million for remitting funds for pending IPO related expenses.
The Holding company received an amount of ₹ 6,373.70 million (net of IPO expenses of ₹ 426.30 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

Objects	Planned net proceeds as per prospectus	Actual net proceeds	Utilisation upto 31 March 2025	Unutilised amount as on 31 March 2025
Repayment/prepayment of all or certain borrowings of Holding Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of Holding Company	550.00	550.00	550.00	-
Pursuing inorganic growth initiatives through acquisitions	278.70	278.70	197.30	81.40
General corporate purposes	1,675.00	1,675.00	1,675.00	-
Total proceeds	6,373.70	6,373.70	6,292.30	81.40

The net IPO proceeds of ₹ 81.40 million which were unutilised as at 31 March 2025 has been temporarily invested in fixed deposit by the Holding company.

- The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Holding Company.
- The Holding Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Holding Company to buyback its equity shares at fair market value in case the Holding Company and/ or its promoters was not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the consolidated financial results of the Group which has been shown separately in the aforementioned consolidated financial results.
However, on 29 May 2024, the Investor have waived off these rights in entirety and accordingly, the Holding Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these consolidated financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from other financial liabilities to other equity in these consolidated financial results.
- During the financial year ended 31 March 2024, owing to floods in Chandigarh and nearby areas, one of the group company had incurred certain damages to inventory along with property, plant and equipment at factory locations in Derra Bassi and Lalru plants amounting to ₹ 251.73 million. The management had filed necessary claims for the damages made with the insurance authorities.

In the current quarter/year, the insurance company has approved a claim of ₹ 77.51 million for the losses at the Lalru site, which has been recorded as an exceptional income in the consolidated financial results and has been received by the group company subsequent to 31 March 2025. Further, following some minor repairs, few machineries were restored to working condition, and the factory building at the Lalru site was considered safe for use after a reassessment that included minor refurbishments. As a result of this reassessment, reversal of losses of ₹ 89.46 million have been recognized as an exceptional income for the year ended 31 March 2025 in these consolidated financial results.

In respect of losses incurred by the group company at its Derrabassi plant, the insurance claim of Rs. 63.73 million was rejected by the insurance company, for which the group company has filed a legal case. Basis on legal precedents and an internal evaluation done by the management, it believes that the group company has a strong possibility of a favorable outcome. Consequently, the group company has recognized this as an exceptional income in the consolidated financial results. However, due to the uncertainty surrounding the recovery of this amount, the group company has created a provision for the same.

(Handwritten signature)



- 8 During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group.
During the search and seizure proceedings, the Group has fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Group continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. The Group has not yet received any written order/ notice/ communication on the findings of such investigation from the department and accordingly, there have been no demands which have been raised on the Group as of date. Based on the foregoing and having regard to the matters of the inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these consolidated financial results for the quarter and year ended 31 March 2025 in this regard.
- 9 During the quarter ended 31 March 2025, as part of group overseas expansion strategy, a subsidiary has been incorporated in UK, Akums Healthcare UK Limited, with an initial investment of GBP 1 done for incorporation purposes.
- 10 The board of directors of the Holding Company have been identified as the Chief Operating Decision Maker (CODM) as defined by Ind AS 108 "Operating Segments". Operating Segments have been defined and presented based on the regular review by the CODM to assess the performance of each segment and to make decisions about allocation of resources. Pursuant to increased focus on branded and trade generics and consequent changes to the nature of internal reporting provided to the CODM, the group has reassessed its reportable segments and have revised the previously reported segments of Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API) and Branded and Generic formulations to the below mentioned segments
- Contract Development and Manufacturing Operations (CDMO): including the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on contract basis, job work and testing services
 - Active Pharmaceutical Ingredient (API): wherein the group is engaged in manufacture and sale of KSM, Intermediate and API products
 - Domestic Branded Formulations: wherein the group undertakes marketing of its branded formulations in the Indian market
 - International Branded Formulations: wherein the group undertakes marketing of its branded formulations in the global market
 - Trade generics: wherein the group leverages trade channel to supply its generic products in the Indian market
- The figures for the previous periods presented in these consolidated financial results have been realigned in accordance with Ind AS 108 "Operating Segments"
- 11 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2024 and management certified year to date figures upto the nine months period ended 31 December 2023.
- 12 The consolidated financial results for the nine months period ended 31 December 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this quarter provide a true and fair view of the group's affairs.

For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited



Sanjeev Jain
Managing Director
DIN: 00323433



Sandeep Jain
Managing Director
DIN: 00323476

Place: New Delhi
Date: 26 May 2025



AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Annexure A1

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai - 400 001

Symbol: AKUMS**Scrip Code: 544222**

Sub: Declaration of Un-Modified Opinion on Annual Audited (standalone and consolidated) Financial Results for the financial year ended 31st March, 2025.


Respected Sir/Madam,

In terms of applicable provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors, Walker Chandiok & Co. LLP, have given unmodified opinion on the Annual Audited (standalone and consolidated) Financial Results of the Company for the financial year ended 31st March, 2025.

For **Akums Drugs and Pharmaceuticals Limited**



Sumeet Sood
Chief Financial Officer



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P





AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Statement of Deviation / Variation in utilisation of funds Raised						
Name of listed entity	Akums Drugs and Pharmaceuticals Limited					
Mode of Fund Raising	Public Issues					
Date of Raising Funds	August 2, 2024 (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited)					
Amount Raised	6800.00 million					
Report filed for Quarter ended	31-03-2025					
Monitoring Agency	Applicable					
Monitoring Agency Name, if applicable	CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	No Comments					
Comments of the auditors, if any	No Comments					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Repayment/ prepayment of indebtedness of the Company	Not Applicable	1,599.10	0	1,599.10	0	-
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	Not Applicable	2,270.90	0	2,270.90	0	-
Funding incremental working capital requirements of our Company	Not Applicable	550.00	0	550.00	0	-
Pursuing inorganic growth initiatives through acquisitions	Not Applicable	278.70	0	197.30	0	-
General corporate purposes (GCP)*	Not Applicable	1,675.00	0	1,675.00	0	-
Total		6,373.70**		6,292.30		



ISO 9001 : 2015
 ISO 14001 : 2015
 ISO 17025 : 2005 (NABL)

WHO-GMP
 US : NSF
 HACCP



AKUMS DRUGS & PHARMACEUTICALS LIMITED


Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

*The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue.

** The amount of original allocation represents the amount raised through fresh Issue net of offer expenses as mentioned in the prospectus dated August 1, 2024.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc


Sumeet Sood
Chief Financial Officer

Date: 26.05.2025

Place: Delhi



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



AKUMS DRUGS & PHARMACEUTICALS LIMITED


Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Annexure - C

Sl. No.	Particulars	Details
1	Reason for change viz. appointment , re- appointment, resignation , removal , death or otherwise	Re-appointment of M/s. Balwinder & Associates, Cost and Work Accountants as Cost Auditor.
2	Date of appointment /re-appointment/ cessation (as applicable) & term of appointment /re-appointment	26.05.2025 for FY 2025-26.
3	Brief profile (in case of appointment)	M/s. Balwinder & Associates, Cost and Work Accountants, is a professional firm providing a wide range of cost and management advisory and compliance services and firm specializes in delivering integrated, technology-enabled solutions in the areas of costing, management, legal, and finance.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure-D

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, re- appointment , resignation , removal , death or otherwise	Appointment of SPG & Associates, Practicing Companies Secretaries as a Secretarial Auditor of the Company.
2	Date of appointment/ re-appointment / cessation (as applicable) & term of appointment / re-appointment	26.05.2025 for five (5) financial years (FY 2025-26 to FY 2029-30) subject to the approval of shareholders at ensuing Annual General Meeting.



ISO 9001 : 2015
 ISO 14001 : 2015
 ISO 17025 : 2005 (NABL)

WHO-GMP
 US : NSF
 H A C C P




AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

3	Brief profile (in case of appointment)	M/s. SPG & Associates, a Peer Reviewed firm of Company Secretaries, established in 2009, at New Delhi, having a rich experience of fourteen (14) years and PAN India presence and specialized in Corporate Laws, Corporate Compliance Management, Secretarial Services, Audits, Insolvency and Bankruptcy, FEMA, IPR, Taxation, Mergers and Acquisition etc. It has a dedicated team of company secretaries committed to delivering timely and practical solutions.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure-E

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation of Mr. Amrut Medhekar, CEO – CDMO Business.
2	Date of appointment/re-appointment/ resignation /-cessation (as applicable) & term of appointment/re-appointment	W.e.f 15.07.2025
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



ISO 9001 : 2015
 ISO 14001 : 2015
 ISO 17025 : 2005 (NABL)

WHO-GMP
 US : NSF
 HACCP



From: [Arvind Kumar Srivastava](#)
To: [Dharamvir Malik](#)
Cc: [sandeep](#)
Subject: FW: Resignation from the Position of CEO
Date: Saturday, May 17, 2025 11:26:08 AM

Dear Dharamvir ji,

FYI and NA pls.

Regards,



Arvind Srivastava
President-HR
Akums Drugs & Pharmaceuticals Limited | Maxcure Nutravedics Limited
Pure & Cure Healthcare Pvt. Ltd. | Malik Lifesciences Pvt. Ltd.
26A, 27 - 30, Sector-8A, IIE, SIDCUL, Haridwar (UK) - 249403
Board: +91-1334-234327/28/29 – Extn No. 7924, Mob: +91 7251033355
Website: www.akums.in; Email: arvind.srivastava@akums.in

From: Amrut Medhekar <amedhekar@yahoo.com>
Sent: 17 May 2025 11:14
To: Sandeep Jain <sandeep@akums.in>; Sanjeev Jain <sjain@akums.net>
Cc: Arvind Kumar Srivastava <arvind.srivastava@akums.in>
Subject: Resignation from the Position of CEO

CAUTION:This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Sir,
Namaskar,
I hope this email finds you well.

As discussed with you, I have decided to step down from my role as CEO. This decision has not been an easy one, but I believe it is the right time for me to pursue new opportunities and challenges.

I am deeply grateful for the trust and support extended to me during my tenure. It has been an honor to lead this organization and work alongside such a talented and dedicated team. We have achieved significant milestones, and I am proud of the progress made at Akums.

To ensure a smooth transition, I am committed to supporting the handover process over the coming weeks. I request you to kindly relieve me on 15th July'25. This support would greatly help me personally & professionally.

Thank you once again for the opportunity to serve & I leave with immense appreciation for the experiences and relationships built here and remain confident in the Akum's continued success.

Warm regards,
Amrut Medhekar.

Click [here](#) to report this email as spam.

Disclaimer: This message may contains legally privileged and/or confidential information. If you are not the intended recipient(s), or employee or agent responsible for delivery of this message to the intended recipient(s), you are hereby notified that any dissemination, distribution or copying of this e-mail message is strictly prohibited. If you have received this message in error, please immediately notify the sender and delete this e-mail message from your computer. WARNING: Computer viruses can be transmitted via email. The recipient should check this email and any attachments for the presence of viruses. The company accepts no liability for any damage caused by any virus transmitted by this email.

This message has been scanned for malware by Websense. www.websense.com